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Abstract Novel methodologies for detection of chromo-
somal abnormalities have been made available in the recent
years but their clinical utility in prenatal settings is still
unknown. We have conducted a comparative study of cur-
rently available methodologies for detection of chromosomal
abnormalitiesafterinvasiveprenatalsampling.Amulticentric
collection of a 1-year series of fetal samples with indication
for prenatal invasive sampling was simultaneously evaluated
using three screening methodologies: (1) karyotype and
quantitativeﬂuorescentpolymerasechainreaction(QF-PCR),
(2) two panels of multiplex ligation-dependent probe ampli-
ﬁcation (MLPA), and (3) chromosomal microarray-based
analysis (CMA) with a targeted BAC microarray. A total of
900pregnantwomenprovidedinformedconsenttoparticipate
(94% acceptance rate). Technical performance was excellent
for karyotype, QF-PCR, and CMA (*1% failure rate), but
relatively poor for MLPA (10% failure). Mean turn-around
time(TAT)was7 daysforCMAorMLPA,25forkaryotype,
and two for QF-PCR, with similar combined costs for the
different approaches. A total of 57 clinically signiﬁcant
chromosomal aberrations were found (6.3%), with CMA
yielding the highest detection rate (32% above other meth-
ods). The identiﬁcation of variants of uncertain clinical sig-
niﬁcance by CMA (17, 1.9%) tripled that of karyotype and
MLPA, but most alterations could be classiﬁed as likely
benign after proving they all were inherited. High accept-
ability, signiﬁcantly higher detection rate and lower TAT,
couldjustifythehighercostofCMAandfavortargetedCMA
as the best method for detection of chromosomal abnormali-
ties in at-risk pregnancies after invasive prenatal sampling.
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During pregnancy management, indications for invasive
prenatal chromosome analysis are usually established
balancing the a priori risk of detectable chromosomal
aberrations in the fetus and the risk of miscarriage asso-
ciated with invasive fetal sampling (Tabor et al. 1986;
MRC working party on the evaluation of chorion villus
sampling 1991). Screening tests, which take into account
maternal age (Cuckle et al. 1987), maternal serum bio-
chemical parameters (Wald et al. 1988; Macri et al. 1991),
and fetal ultrasound markers (Benacerraf et al. 1987), are
used to provide a risk assessment for Down syndrome,
neural tube defects, and many fetal malformations, but are
not useful biomarkers for other medical conditions. At
present, various screening strategies and diagnostic meth-
ods are implemented in different countries.
G-banding karyotype analysis became the gold standard
for detection of fetal chromosomal abnormalities in the
1970s (Steele and Breg 1966; Caspersson et al. 1970).
Nevertheless, a number of chromosomal defects associated
with moderate to severe clinical conditions, including
genomic disorders and subtelomeric rearrangements (Flint
et al. 1995), fall below the resolution limit of the karyo-
type (\5–10 Mb). In addition, karyotyping requires living
cells, which increases turn-around time (TAT), risk of
culture artifacts, and might prevent the analysis in situa-
tions where cell viability is compromised (i.e. products of
conception).
Fluorescent in situ hybridization (FISH) on interphase
nuclei, quantitative ﬂuorescent PCR (QF-PCR) (Mansﬁeld
1993; Pertl et al. 1994), and multiplex ligation-dependent
probe ampliﬁcation (MLPA) (Schouten et al. 2002) have
emerged as rapid (less than 3 days) alternatives for detec-
tion of a discrete number of chromosomal aneuploidies or
submicroscopic rearrangements. Experimental and clinical
data gathered for years has prompted the routine adoption
of QF-PCR or FISH (Blennow et al. 1994) together with
conventional banding cytogenetics as the standard of care
for prenatal detection of chromosomal abnormalities in at-
risk pregnancies in many countries (Shaffer and Bui 2007).
Chromosome microarray analysis (CMA) combines
short TAT and high resolution with massive analysis of
copy number variation throughout the genome. In contrast,
it cannot identify balanced rearrangements, is still rela-
tively expensive, and may detect a number of variants of
uncertain clinical signiﬁcance (VOUS). While SNP-based
microarrays are able to detect polyploidies and uniparental
disomies, purely CGH-based platforms (like the BAC-
based used in this study) are not capable of identifying such
events.
Extensive experience has already been acquired with the
use of MLPA and CMA in postnatal diagnosis of multiple
conditions. Recently, a consensus document has been
published on the clinical suitability of CMA as the ﬁrst-tier
method for the study of cases of intellectual disability or
congenital malformations (Miller et al. 2010). An eco-
nomic evaluation also demonstrated that in postnatal
analysis, the preferential use of CMA instead of karyotype
is cost effective (Regier et al. 2010). It is also relevant the
high detection rate of genomic imbalances in neonates with
birth defects shown by CMA (Lu et al. 2008). Although
several studies have been published to date suggesting
higher detection rates (Sahoo et al. 2006; Van den Veyver
et al. 2009; Maya et al. 2010), prenatal CMA experience is
still limited and no prospective studies have been addressed
to demonstrate the clinical utility of this novel technology
in prenatal settings.
We present here the results of a multicentric compara-
tive study of clinical utility (i.e. likelihood that a test will
lead to an improved health outcome) and costs of chro-
mosomal aberration detection methods in invasive prenatal
diagnosis of 900 consecutive pregnant women with indi-
cation for fetal sampling.
Subjects and methods
Subjects
The entire study received Institutional Review Board
approval from the Ethics Committees for Clinical
Research of both participating institutions. A consecutive
series of pregnant women referred to the obstetrics
departments of the Hospital Universitario La Paz (Madrid)
and Hospital Universitari Vall d’Hebron (Barcelona), both
public hospitals of the Spanish health system, between
February 2009 and March 2010 for prenatal invasive fetal
sampling were offered to participate in the study after a
pre-test session of genetic counseling. In this session, we
explained their risk for fetal anomalies and the methods of
sampling and analyses. We discussed with couples the
beneﬁts, limitations and timing for result delivery in rou-
tine analysis (karyotype and QF-PCR), as well as the
possibility to extend prenatal studies with additional
analysis (MLPA and CMA) with the a priori beneﬁts,
limitations and timing of those studies. The possibility to
detect a higher number of genomic alterations of unknown
signiﬁcance was also discussed. During the ﬁrst 6 months
of the study, 402 pregnant women were also invited to
answer a short questionnaire on socio-demographic char-
acteristics, subjective anxiety levels, and the reasons to
accept or refuse prenatal diagnostic tests with novel
technologies.
A total of 900 women who provided informed consent
entered the study, and 906 fetal samples were obtained
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123(6 twin gestations). Main indications for sampling were
abnormal ultrasound ﬁndings, altered biochemical screen-
ing, familial history of chromosomopathy or other genetic
condition, advanced maternal age ([37 years old) and
other exceptional conditions (high-risk twin pregnancy,
suspected viral infection, among others) (Table 1). Fetal
samples referred for maternal anxiety were also included in
the study, although this is not an indication of recognized
high risk of chromosomopathy.
A post-test genetic counseling session was provided in
all cases when a genetic alteration was detected by any
method. The most important topic of this session was the
clinical relevance and prognosis of the detected alteration,
considering the possibility of incomplete penetrance and/or
variable expressivity, along with the appropriateness of
further genetic analysis in the parents to determine if the
alteration was inherited or de novo.
The nature of the collected fetal sample mostly depen-
ded on the gestational age at the indication for sampling.
Chorionic villus samples (CVS) were obtained from ges-
tations in the range of eight to 14 weeks (n = 164, 18.0%),
amniotic ﬂuid (AF) through amniocentesis from weeks 15
to 21 (n = 728, 80.0%), and fetal blood (FB) by funicu-
locentesis at 20–22 weeks (n = 14, 2.0%). In order to
warrant the optimal performance of the standard clinical
testing, a minimum sample size was allocated for QF-PCR
and karyotyping (0.5 mg of CVS, 12 mL of AF and
300 lL of FB), while the remaining was used for DNA
isolation (at least 0.5 mg for CVS, 4 mL for AF, or 300 lL
for FB, based on previous data). Therefore, only samples
with more than 1 mg of CVS, 16 mL of AF and 600 lLo f
FB, were processed in the study.
Statistics
Exact binomial conﬁdence limits were calculated to test
sensitivity, speciﬁcity, and positive and negative predictive
value as previously described (Collet 1999). We also
computed the diagnostic accuracy, deﬁned as the propor-
tion of all tests that give a correct result. Finally, Youden’s
index was computed as the difference between the true
positive rate and the false positive rate. Youden’s index
ranges from -1t o?1 with values closer to one if both
sensitivity and speciﬁcity are high (Altman et al. 2000).
Calculation of costs
We calculated the cost per test and the cost per diagnosis
associated with each technology based exclusively on
direct costs including consumables (reagents) and person-
nel costs in Spain (2010 prices). We estimated hands-on-
time per laboratory technician for performing assays, and
genetics specialist for data analysis and interpretation, and
assumed an average of 20 samples analyzed per week. The
cost per diagnosis was calculated on the basis of the costs
and diagnostic outcomes (number of diagnoses) of the 906
samples analyzed in our study. We also attempted to esti-
mate a rough incremental cost-effectiveness ratio (ICER).
The ICER is given by the ratio of the difference in costs
between technologies (incremental costs) and the differ-
ence in effects or outcomes (incremental effects); this ratio
represents the additional cost per extra unit of effect/out-
come of one technology in comparison with another
(Drummond et al. 2005). In this study we estimated a rough
ICER of CMA in comparison with karyotype, considering
Table 1 Indications for sampling and abnormality detection rates
Indication Number of
indications
Alterations with
phenotypic consequences
a
Detection method
b
QF-PCR CMA Karyotype MLPA
Abnormal ultrasound 173 23 (13.3) 14 (61) 22 (96) 16 (69) 12 (52)
Biochemical screening 235 12 (5.5) 11 (92) 12 (100) 11 (92) 12 (100)
Family history 145 8 (5.5) 1 (12) 8 (100) 5 (62) 5 (62)
Advanced maternal age 273 11 (4.0) 6 (55) 11 (100) 8 (73) 7 (64)
Other
c 20 2 (10.0) 2 (100) 2 (100) 2 (100) 2 (100)
Maternal anxiety 60 1 (1.7) 0 (0) 1 (100) 0 (0) 1 (100)
Total number 906 57 34 (60) 56 (98) 42 (74) 39 (68)
6.3% 3.6% 6.2% 4.6% 4.3%
In pregnancies with more than one indication, only the indication with higher a priori risk (ranked from top to bottom) was recorded
a Number of alterations identiﬁed that are reported in the bibliography to have phenotypic effects. This column comprises the pathologic and
clinically relevant categories. The percentage of alterations with phenotypic consequences from the total of cases from each indication is shown
in brackets
b Bracketed values indicate the percentage of alterations with phenotypic consequences from each indication category that were detected by each
method
c Includes multiplex pregnancy, viral infection, and other rare indications
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123the number of diagnoses as a measure of effects, although
we are aware that this is an intermediate outcome.
Results
Acceptance of novel prenatal testing procedures
All women who answered the questionnaire after the pre-
test counseling session (402/402) considered to have
received enough information of the ongoing study in order
to make a decision about participation. Among the 94%
who decided to participate, the main motivations were to
obtain more information (45%), to contribute to scientiﬁc
progress (48%), to decrease anxiety (5%), and in gratitude
for the professional kindness (1%). Fifty-six women (6%)
declined to join the study but continued with standard
prenatal testing; 60% of them argued more anxiety due to
extra testing. The median level of perceived anxiety prior
to testing was three on a scale between one (very low) and
ﬁve (very high), mostly due to the reason for referral for
prenatal testing. The fact of entering the study did not
represent any additional source of stress in those who
accepted participating.
Technical performance and turn-around-time
Good quality DNA for the different analyses was obtained
from 95% of CVS, 100% from FB, and 56% from AF
uncultured samples; thus it was necessary to obtain DNA
from cultured chorionic villi and amniotic ﬂuid in 5% and
in 44% of the cases, respectively (Supplementary Table 1).
One advantage of performing multiple techniques on the
same sample was that failures could be attributed to either
a single technology or the common manipulation in most
cases. We considered a technical failure when it was not
possible to provide a deﬁnitive result with that technology
for any reason. Karyotype was the most robust technique
with only eight failures (0.9%), all cases due to cell culture
failure. CMA showed a failure rate of 1.1% (10/906), the
same as QF-PCR, but seven out of the ten failing samples
had been extracted the same day. MLPA was the less
robust technique, with a failure rate of 10.1% (183/1812),
61 with the subtelomeric set of probes and 122 to the
genomic disorders (RGD) set (see Supplementary Meth-
ods). In most cases, MLPA failure was attributable to
uncertainty in the interpretation of noisy electropherograms
with variable peak heights.
TAT was measured since the arrival of the biological
sample to the laboratory and until the results of the main
test were obtained. Time for downstream analysis of the
ﬁndings (parental testing, validation by an alternative
genetic test, etc.) was not computed to determine the TAT
mainly because additional samples were not readily
available (parental samples were not collected on a regular
basis), and because the approaches required for validations
were different for each case and technology. Overall,
QF-PCR was the fastest technique generating results with
an average TAT of two working days, while the average
TAT for CMA and MLPA from uncultured specimens was
7 days. For cultured samples, including G-banding karyo-
type, average TAT ranged between 4 and 27 days
(Supplementary Table 1).
Chromosomal aberrations detected
A total of 100 chromosomal aberrations were identiﬁed in
95 different samples and were classiﬁed into different
categories according to their predicted clinical signiﬁcance
(Tables 2, 3, and Supplementary Table 2 for detailed
description). In the Pathologic category we detected 26
trisomies, 3 triploidies, 3 derivative/marker chromosomes,
6 segmental aneuploidies and 2 fully penetrant microde-
letion disorders. Seventeen fetuses were observed to carry a
clinically relevant alteration, including 11 sex chromosome
aneuploidies and six recurrent microduplication syn-
dromes. Twenty-one aberrations corresponded to the
Uncertain Relevance category, four cytogenetically bal-
anced rearrangements and 16 copy number alterations,
three of them in malformed fetuses. The Benign category
was composed of 22 variants. Although cross-validation
was provided by the simultaneous use of multiple tech-
nologies in most cases, we used additional molecular
techniques in the follow-up of some of the alterations
identiﬁed by CMA, including the analysis of parental
samples to deﬁne whether the rearrangements were de
novo or inherited (Table 3 and Supplementary Table 2). As
an example, FISH was used for conﬁrmation of the carrier
status for a balanced rearrangement in the mother of a fetus
with an unbalanced alteration (Supplementary Figure 1).
Sensitivity, speciﬁcity and detection rates
The nature and resolution of the assessed technologies
necessarily impact on the ﬁnal detection rate achieved by
each of them, with intrinsic a priori limitations. In order to
perform a comparative evaluation of the different methods
by means of speciﬁcity and sensitivity, we used all chro-
mosomal abnormalities identiﬁed with predictable clinical
outcome, regardless of its size, as the one-for-all measure
unit. Speciﬁcity was found to be very high in all cases,
above 99% for QF-PCR, karyotype, and CMA, and 97%
for MLPA. However, sensitivity was signiﬁcantly higher
for CMA (98.2%) than for other technologies (Table 4).
Youden’s index also revealed that CMA combines the
highest true to false positive ratio.
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123The overall detection rate of pathological and clinically
relevant alterations was 6.3% (57/906 samples) with dif-
ferent detection capabilities depending on the technology
(Table 1). CMA yielded a superior detection rate in fetuses
with abnormal ultrasound (13.3%), but it was also signiﬁ-
cant in pregnancies with a priori low risk (1.7 and 4.0%,
anxiety and advanced maternal age with normal screening,
respectively) (Table 1), far above the risk of pregnancy
loss by invasive sampling (Driscoll and Gross 2009).
Overall, CMA detected 32% more alterations than QF-PCR
and karyotype, including eight conditions with rather poor
prognosis for postnatal development (Table 3). This per-
cent increase in detection rates was equally high among
low-risk pregnancies and on those with an ultrasound
anomaly (Supplementary Table 3).
Another advantage of CMA was the ability to better
characterize two supernumerary markers (sSMC) and a
derivative chromosome identiﬁed by karyotyping (Table 3).
Interpretation and reporting criteria
Interpretation of results in studies using targeted CMA is
conceptually more straightforward than in studies using
whole-genome microarrays, although no increase of unclear
results has been reported in previous comparative studies
(Coppinger et al. 2009). Although a great effort was made to
Table 2 Chromosomal alterations identiﬁed with the different technologies
Methods
QF-PCR CMA Karyotype MLPA
a Total
Pathologic (de novo)
b 40
Trisomies 21 26 25 22 26
Triploidy 3 2 3 0 3
Marker/derivative 0 3 3
c 23
Segmental aneusomy
Non-recurrent 0 6
d 13 6
Genomic disorder 0 2
e 01 2
Clinically relevant (de novo and inherited)
f 17
Sex chromosome aneuploidy
g 10
e 11
e 10
e 91 1
Microduplication/incomplete penetrance 0 6 0 3 6
Subtotal 34
3.8%
56
6.2%
42
4.6%
39
4.3%
57
6.3%
Uncertain relevance (VOUS—de novo and inherited)
h 21
Visible phenotype 0 3 0 0 3
Unpredictable phenotype 0 14 3 2 18
Benign
i 22
01 8 4 1 2 2
Total 100
Chromosomal alterations were classiﬁed into different categories according to the prediction of potential clinical consequences
Some samples were found to carry more than one chromosomal alteration (see Supplementary Table 2) and each individual event was counted
accordingly in this table, except in the cases speciﬁed herein
a Combines detection of the subtelomeric and genomic disorder probe mixes
b Pathologic: rearrangements with a priori fully penetrant, predictable phenotype (trisomies, triploidies, derivative/marker chromosomes,
segmental aneusomies and fully penetrant microdeletion disorders)
c sSMCs/derivative identiﬁed but of unknown origin
d One of the cases with two inherited CNVs plus a de novo alteration
e Sample with two alterations: trisomy X and 22q11.21 distal microdeletion
f Clinically relevant: rearrangements that can lead to potentially serious manifestations (neurobehavioral phenotypes, congenital anomalies,
intellectual disability, etc.), but with incomplete penetrance and/or highly variable expressivity (sex chromosome aneuploidies and recurrent
microduplication syndromes)
g Includes a segmental aneusomy Xp (sample 10F05P)
h Uncertain relevance: variants of unpredictable phenotype, not reported previously in normal controls or in (novel cytogenetically balanced
rearrangements, novel copy number alterations and/or partially overlapping with variants in the DGV)
i Benign are variants that coincide with rare CNVs previously reported in few individuals with no disease phenotype, including events
overlapping segmental duplications, without genes, or found more than once in our series
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123avoid using probes coinciding with polymorphic copy
number variants (CNVs), this was not possible for two main
reasons. First, when the array was designed, the knowledge
of the genome distribution of CNVs was limited; and sec-
ond, in order to interrogate some speciﬁc syndromes it was
necessary to use probes located in variable regions.
Alterations coinciding with known polymorphic CNV
regions were interpreted as benign and not included in the
analysis report. Alterations identiﬁed in a region involved
in a known microdeletion/microduplication syndrome were
reported as pathogenic. Variants not falling into these two
categories were classiﬁed as VOUS.
The identiﬁcation of VOUS in prenatal testing is chal-
lenging and disturbing, since a clinical and prognostic
interpretation is required. As a general rule, a genomic or
cytogenetic variant is considered benign when it is inher-
ited from a disease-free parent. However, there is always a
risk in inherited variants due to incomplete penetrance or
different parent-of-origin effects, while de novo events
may also be benign. Two VOUS were detected by MLPA
(0.2%), 3 by kayotyping (0.3%), none by QF-PCR, and 17
by CMA (1.9%), 3 of these in fetuses with ecographic
malformations. All of those detected by karyotype or
MLPA, and six out of seven detected by CMA and after-
wards validated, were inherited from normal parents and
thus considered presumably benign. The remaining 11
parents were informed and declined to undergo further
genetic testing as this would have not had any impact on
modifying the VOUS condition of the ﬁndings.
Costs
The cost per test ranged between €37 (QF-PCR) and €242
(CMA). QF-PCR was the less costly technology but it was
also the technology that yielded less number of diagnoses.
On the contrary, CMA yielded the highest number of
diagnoses but being also the most expensive (Supplemen-
tary Table 4). As a result, the cost per diagnosis ranged
between €991 (QF-PCR) and €3,916 (CMA). In our study,
the only technology that became dominated was the com-
bination of karyotype and QF-PCR (the current standard in
several EU countries, including Spain), that is, the com-
bination was more costly than and as effective as karyotype
alone. A rough estimation showed an ICER of €6,442 per
additional diagnosis with CMA in comparison with
karyotype, and €4,034 if we compared CMA with karyo-
type plus QF-PCR.
Discussion
We have observed a very high acceptability of novel
techniques for prenatal diagnosis after appropriate genetic
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123counseling, with only 6% of women declining to enter the
study due to increased anxiety. Technical performance was
excellent for CMA, and similar to QF-PCR or karyotype
under standard procedures. However, despite our extensive
experience with the technology, MLPA showed a high rate
of technical failure in uncultured AF samples, likely due to
the low purity of the DNA obtained (salt and/or protein
contamination). Finally, CMA revealed to be the most
sensitive technique for diagnosing chromosomal alterations
associated with medical conditions, being able to detect all
but one clinically relevant alterations (56/57), followed by
G-banding karyotype (42/57), MLPA (39/57) and QF-PCR
(34/57, all detected by karyotype as well). In other words,
CMA increased *32% the detection rate of any other
method. Conversely, the only clinically relevant alteration
missed by CMA was a triploidy with karyotype 69, XXX,
associated with a usually lethal condition in utero. This
limitation could be overcome using microarrays that also
interrogate nucleotide variation (SNPs), that can also detect
uniparental disomies, but their clinical utility in prenatal
setting remains to be proven. There was also a qualitative
advantage of CMA, as the origin of small supernumerary
marker chromosomes and derivatives was readily deter-
mined. Maybe the most relevant implication of our data is
that 14 relevant fetal conditions (*1.6% of the entire
study) would have remained undiagnosed using only the
currently implemented detection methods in the clinic. The
use of CMA resulted in an increased detection rate
regardless of the indication for study. This becomes espe-
cially evident in the high-risk group (ultrasound ﬁndings),
in which the percentage of detection was elevated to
13.3%; but also in groups with a priori low risk, which
showed a detection rate far above 1/100 and a relative
increase over 45% when compared to currently imple-
mented methods (Supplementary Table 3).
Since a decision on the continuation of a pregnancy
might follow the diagnostic ﬁndings of a prenatal test, it is
not desirable to identify VOUS and there are some difﬁ-
culties dealing with some clinically relevant conditions
with variable expressivity or incomplete penetrance. We
tried to minimize VOUS by designing a targeted micro-
array, that interrogates only regions of known clinical
relevance and using large segments of DNA as probes, and
MLPA panels were also selected with similar criteria.
Overall, CMA detected 17 of the total 21 VOUS identiﬁed,
although 3 of them might be causative as they were found
in fetuses with malformations. Most VOUS could be
classiﬁed as likely benign after proving they all were
inherited from a parent with no-disease phenotype. For the
management of such ﬁndings, it is of extraordinary help the
development of public and trustable databases of variation
on normal individuals, such as the database of genome
variants (DGV) and the initiatives to catalogue normal and
pathological variation from the ISCA and DECIPHER
consortia. The minimization of VOUS is just a matter of
time and of better describing structural variation in larger
cohorts of cases and controls by means of different -omic
approaches, which would allow establishing a solid statis-
tical framework for assigning (or not) pathogenicity to each
speciﬁc copy number variant. In such a future scenario, the
use of higher genome coverage approaches might be
preferred.
Interestingly, we detected six cases of recurrent micro-
duplication syndromes (0.7% of our series), three inherited
from a phenotypically normal parent and three de novo. We
faced the difﬁcult counseling of these genomic imbalances
associated with variable phenotypes and incomplete pene-
trance with still scarce literature, although preliminary
guidelines for clinical evaluation and anticipatory guidance
have been published (Berg et al. 2010). Following a
20-week normal ultrasound evaluation, the parental deci-
sion in all cases was continuation of the pregnancy. The
situation, however, is comparable to the counseling of sex
chromosome aneuploidies, where the phenotype can be
very mild with incompletely penetrant features.
In order to provide further objective assessment tools,
we also estimated the costs of the different technologies.
Although CMA is still the most expensive technology, it is
also the one that yields a higher number of diagnoses. Our
cost analysis study had some limitations related to the non-
inclusion of some relevant costs like equipment deprecia-
tion and maintenance, as well as costs of downstream
analyses required for conﬁrming ﬁndings. Our rough esti-
mation indicates that expenses not included in our cost
analysis (mainly capital expenses to set up a clinical lab-
oratory and direct maintenance costs) are similar for the
different platforms. Thus, the most important direct costs
were included and the ﬁgures reported herein can show the
relative differences between technologies. The other limi-
tation was the use of number of diagnoses as outcome
measure instead of a health-related outcome (Grosse et al.
2008). Therefore, the estimated ICER is a tentative ﬁgure
reported here with the aim of promoting the debate about
the willingness to pay for new technologies and to show the
need of economic evaluations in the ﬁeld of genetic
screening and diagnosis (Carlson et al. 2005). A full eco-
nomic evaluation will be addressed in the future.
In summary, our data indicate that from the perspective
of diagnostic capacity, sensitivity, and speciﬁcity, CMA is
the most reliable technology. According to women’s
acceptance, the diagnostic yield increase that CMA brings
into prenatal genetic testing of risk pregnancies, the
extraordinary medical and social cost of birth defects
associated to chromosomal disorders, and until non-inva-
sive methods are able to provide a similar sensitivity, we
consider that CMA should already be a ﬁrst-tier option for
Hum Genet (2012) 131:513–523 521
123invasive prenatal diagnosis of at-risk pregnancies instead
of the current combination of RAD (QF-PCR or FISH) and
karyotype.
Although non-invasive assays for fetal diagnosis are an
intense ﬁeld of research, at present these are only experi-
mental approaches available for speciﬁc chromosomal or
single gene disorders (Chiu et al. 2011). Thus, nowadays,
invasive fetal sampling is still the common practice, indi-
cated in those cases where the risk of a detectable abnor-
mality in the fetus is above the risk of a procedure-related
pregnancy loss, *1/200 (Driscoll and Gross 2009). While
the evaluation of larger series is granted, the much higher
detection rate of CMA, even in a priori low-risk groups
([1/100), should open the door to consider even deeper
changes in currently established screening policies in pre-
natal care.
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